
UNC Health clinicians encourage assessment of memory changes. Learn how testing fits together and why early-treatment claims need context.

On October 2, 2026, ABC11 reported that clinicians at UNC Health’s Memory and Aging Brain Clinic encouraged people noticing memory changes to seek assessment rather than wait for severe symptoms.
According to ABC11, patients reach the clinic through a referral from a primary care physician. Neurologist Dr. Hannah Noah described a series of appointments that begins with detailed neurocognitive testing. That testing examines strengths and weaknesses in memory and whether the pattern suggests a particular syndrome.
This gives the assessment a specific purpose: describing a pattern of performance. The clinic is not simply recording that someone feels their memory has changed. It is examining that concern in detail through testing, according to Noah’s account.
Neuropsychologist Andrea Kurasz told ABC11 that test results are compared with normative data. These are comparison results from people with similar backgrounds. Factors include age and sometimes education, with gender also mentioned in her explanation.
That comparison gives a score a reference point. The question is how this person’s performance compares with that of people whose backgrounds are similar. This is part of the interpretation Kurasz described, rather than a score being read in isolation.
ABC11 reported that clinic providers use written assessments, scans and blood tests together to build a fuller picture. Dr. Noah said blood testing can detect protein changes in the brain. She described it as less expensive and less invasive than options previously available.
Readers seeking more background on this process can read about how cognitive testing fits into a broader evaluation. The relevant point in the UNC Health account is that clinicians bring several kinds of information together.
Dr. Noah’s message was that noticing a memory change and wanting to understand its cause is enough reason to seek an assessment. People do not need to wait until symptoms become severe before raising that concern, according to her comments to ABC11.
A practical first step consistent with the report is to discuss new or persistent changes with a primary care physician. The conversation can include whether a referral for cognitive assessment is appropriate. That follows the route described for UNC Health’s clinic.
Questions grounded in the clinic’s reported process include:
These questions focus on understanding the purpose of an assessment. They do not ask the person with the concern to interpret test results or identify a disease. For related background, see a closer look at early cognitive changes.
Dr. Noah also explained why timing may matter for some treatment discussions. She told ABC11 that infusion medicines targeting a protein associated with Alzheimer’s work best in early disease stages. That is the report’s treatment-related reason for encouraging evaluation before symptoms become severe.
The report’s encouragement to seek assessment does not mean new memory changes necessarily indicate Alzheimer’s disease. Its practical message concerns getting a question assessed, rather than assigning a diagnosis before testing.
A 2026 review summary in Neurological Sciences addressed amyloid-targeting antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s. It described the average effects on cognitive function and dementia severity at 18 months as “trivial.” The summary also reported increased amyloid-related imaging abnormalities, known as ARIA.
This adds needed context to Dr. Noah’s comments. Saying a medicine works best in an early stage does not establish that its average benefit is large. The clinic report presents a clinician’s explanation of treatment timing, while the review summary addresses the size of average clinical effects and a reported risk.
The review’s description is about average results in the specified patient groups. It should not be turned into a prediction for every individual. Personal decisions about these treatments belong with a qualified clinician who can assess the person’s situation and discuss the evidence.
ABC11 also reported that there is no cure for Alzheimer’s disease or dementia. Early assessment does not guarantee treatment eligibility, and the report does not establish that treatment restores lost memory. The coverage provides no detailed treatment-selection criteria or independent trial results.
The ABC11 story does not identify the specific blood test, report its accuracy or establish that every patient receives it. It also does not support treating a blood result alone as confirmation of Alzheimer’s disease. The same caution applies to interpreting one scan or cognitive score by itself.
The practical question for a clinical conversation is how each result contributes to the complete assessment. That stays close to the process described in the report: several kinds of evidence interpreted together. It keeps attention on the clinician’s overall evaluation rather than on the appeal of one newer test.
ABC11 described the clinic as a “one-stop shop,” but Dr. Noah described a series of appointments. The story does not provide wait times, appointment costs or insurance information. Those practical details need to be checked with the relevant care team rather than inferred from the description.
For readers outside this clinic’s referral pathway, the supported starting point remains a conversation with a primary care physician. The report describes how one clinic approaches memory concerns, not a universal access process for every health system.
The value of the UNC Health report is its focus on understanding a change before deciding what it means. It gives adults noticing memory problems a clear subject to raise with their physician: whether an assessment would help explain the concern. That is a practical message without requiring a frightening assumption about the cause.
For long-term cognitive health, careful assessment and careful interpretation belong together. The clinic account shows the work involved in building a picture from different kinds of evidence. The treatment review shows why that same care is needed when judging claims about benefit. Better questions are a sound starting point for both conversations.
When early memory assessment leads to questions about treatment claims, FitBrainLab helps readers understand the research behind those claims. For adults 60+ who find established evidence hard to separate from hopeful headlines, its research-led explanations put brain-aging findings into clear language without fear or hype.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.



Build habits that support memory, focus and a curious, connected life.
Read the Blog